Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Rating of “Hold” from Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given an average recommendation of “Hold” by the seventeen brokerages that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $45.50.

Several research analysts have commented on the stock. KeyCorp initiated coverage on shares of Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating for the company. Barclays initiated coverage on shares of Hims & Hers Health in a research note on Monday, December 8th. They issued an “overweight” rating and a $48.00 price target for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a research report on Friday, September 12th. UBS Group set a $32.00 target price on Hims & Hers Health in a research report on Tuesday, November 4th. Finally, BTIG Research restated a “buy” rating and issued a $85.00 target price on shares of Hims & Hers Health in a research note on Tuesday, November 4th.

Hims & Hers Health Stock Down 0.8%

NYSE HIMS opened at $34.54 on Friday. Hims & Hers Health has a 1 year low of $23.97 and a 1 year high of $72.98. The stock has a market capitalization of $7.86 billion, a PE ratio of 63.95, a PEG ratio of 6.86 and a beta of 2.41. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The business’s 50-day moving average is $40.01 and its 200 day moving average is $47.98.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The business had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. Hims & Hers Health’s quarterly revenue was up 49.2% on a year-over-year basis. During the same period last year, the firm posted $0.32 earnings per share. Sell-side analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health announced that its Board of Directors has approved a share buyback plan on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 3% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other Hims & Hers Health news, COO Michael Chi sold 13,750 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $504,762.50. Following the sale, the chief operating officer directly owned 305,161 shares in the company, valued at approximately $11,202,460.31. This trade represents a 4.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Irene Becklund sold 8,411 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the transaction, the insider owned 2,126 shares in the company, valued at approximately $78,045.46. This trade represents a 79.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 230,835 shares of company stock worth $11,113,714 over the last 90 days. Corporate insiders own 13.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Farallon Capital Management LLC increased its stake in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after buying an additional 2,533,271 shares during the period. Invesco Ltd. grew its stake in Hims & Hers Health by 502.2% in the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock worth $127,237,000 after acquiring an additional 2,128,587 shares in the last quarter. Clear Street LLC purchased a new position in shares of Hims & Hers Health during the second quarter worth approximately $83,582,000. Norges Bank purchased a new stake in shares of Hims & Hers Health in the second quarter valued at approximately $78,464,000. Finally, Clear Street Group Inc. bought a new position in Hims & Hers Health in the third quarter worth approximately $87,372,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.